Skip to content

The Effect of Genetic Variation in TMPRSS6 Gene (SNP rs855791) on Oral Iron Absorption: an Iron Stable Isotope Study

The Effect of Genetic Variation in TMPRSS6 Gene (SNP rs855791) on Oral Iron Absorption: an Iron Stable Isotope Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03317873
Enrollment
80
Registered
2017-10-23
Start date
2017-11-01
Completion date
2019-02-19
Last updated
2019-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Metabolism Disorders

Brief summary

Iron deficiency is considered the most common nutritional deficiency worldwide and affects children and women in both non-industrialized as well as industrialized countries. The main regulatory molecule of iron metabolism is hepcidin, a hormone produced in the liver that regulates intestinal iron absorption, placental transport, recycling of iron by macrophages and release from stores. The expression of hepcidin is regulated by many mediators, one of which is Matriptase-2 - a transmembrane protease. Complete loss of function leads to the rare disease iron-refractory iron deficiency anemia (IRIDA). Matriptase-2 is encoded by the gene TMPRSS6 and the single nucleotide polymorphism (SNP) rs855791 causes a non-synonymous substitution (V736A) that reduces the activity of the protease to inhibit hepcidin transcription. Genome wide association studies have identified the TMPRSS6 SNP rs855791 has a strong association with red blood cell and iron parameters in the general population. The objectives of the study is to measure oral iron absorption and systemic iron utilization into red blood cells (RBC) using oral isotopic labels in subjects homozygotes for common variants of the TMPRSS6 gene with the SNP rs855791 (A736V); AA vs. VV subjects. The aim is to conduct an iron absorption study in 80 Taiwanese women of reproductive age, non-pregnant, non-anemic, investigating the effect of the genetic variants of the SNP rs855791. The participants will be split in two groups of equal size; wild type AA vs. mutation VV. Iron absorption and systemic utilization will be assessed by two test meals containing stable isotopes of iron.The primary outcome of the trial is the oral iron absorption from a test meal as compared between the two genotypes AA vs. VV. Secondary outcomes are the comparison iron status markers between the two genotypes.

Interventions

DIETARY_SUPPLEMENTTestmeal A

The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

DIETARY_SUPPLEMENTTestmeal B

The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

Sponsors

Chang Gung Memorial Hospital
CollaboratorOTHER
Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects homozygotous for the for AA (CC), or VV (TT) variant of the SNP rs855791 of the TMPRSS6 gene. * Females 20 - 45 years of age (premenopausal status) * obtained informed consent * regular menstrual cycle, ± 2 days

Exclusion criteria

* Pregnancy or lactating (assessed by pregnancy test and self-declaration, respectively) * Anemia defined as Hb \< 120 g/L * Plasma ferritin \< 30 µg/l, or \> 120 µg/l * C-reactive Protein \> 5 mg/l * Body weight \> 65 kg * Body mass index (BMI) 18.5 - 25 * Diagnosed metabolic or gastrointestinal disorders, eating disorders or food allergy to the ingredients of the test meal. * Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months, prior the first study day. * Subjects who cannot be expected to comply with study protocol (e.g. non-residents). * Use of long-term medication during the study * Subjects that will take part of another clinical study at the same time or had within the last 30 days before the first study day * Intake of mineral/vitamin supplements 2 weeks before the first study day and during the study

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in the isotopic ratio of iron in blood at week 2baseline, 2 weeksThe change in the isotopic ratio of iron in blood will be measured after the administration of test meal including iron isotopes.

Secondary

MeasureTime frameDescription
hepcidinbaselinefasting concentrations of plasma hepcidin in AA and VV variants of SNP rs855791
iron statusbaselineThe difference in fasting concentrations of serum iron, transferrin saturation, serum ferritin, hemoglobin, erythrocyte volume in AA and VV variants of SNP rs855791

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026